Agile Therapeutics Revenue, Profits - AGRX Quarterly Income Statement

Add to My Stocks
$0.58 $0 (0%) AGRX stock closing price Jun 21, 2018 (Closing)

AGRX stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Agile Therapeutics stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from - to - and how operating and non operating activities have impacted the AGRX stock. The Agile Therapeutics profit and loss statement for 2018 Q1 shows a net profit of $-6.83M. Profits for last year was $-6.24M. Apart from this an investor should also check Agile Therapeutics assets and Agile Therapeutics free cash flow.

View and download details of revenue and profits for Agile Therapeutics for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Agile Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Agile Therapeutics Gross Profit
Research & Development Expense3.96M2.74M3.17M3.79M4.72M5.52M4.91M5.57M4.92M6.93M
Selling General & Admin Expense3.08M3.27M3.52M3.19M2.4M2.3M2.18M2.26M2.05M2.26M
Income Before Depreciation Depletion Amortization-7.04M-6M-6.7M-6.99M-7.12M-7.81M-7.09M-7.84M-6.98M-9.17M
Depreciation Depletion Amortization----------
Non Operating Income--------0.02M--0.15M
Interest Expense----------
Agile Therapeutics Pretax Income
Provision for Income Taxes-0.47M-----3.07M----5.97M
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-6.83M-6.24M-7.1M-7.45M-7.52M-5.2M-7.8M-8.42M-7.32M-3.9M
Extraordinary Items & Discontinued Operations----------
Agile Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS34.23M34.18M31.94M28.8M28.77M28.76M28.76M28.74M26.83M22.3M
Average Shares used to compute Basic EPS34.23M34.18M31.94M28.8M28.77M28.76M28.76M28.74M26.83M22.3M
Income Before Nonrecurring Items-7.33M-6.24M-7.1M-7.45M-7.52M-8.28M-7.8M-8.42M-7.32M-3.9M
Income from Nonrecurring Items-----3.08M----
Agile Therapeutics Earnings Per Share Basic Net
Agile Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.21-0.18-0.22-0.26-0.26-0.29-0.27-0.29-0.27-0.17
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

It is very helpful to read a report on Agile Therapeutics stock analysis. An investor must check the following items in an income statement:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this quarter of 2018 Q1. Our Agile Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. AGRX stock had a poor bottom line growth.

The income statement is also called statement of revenue and expense. The AGRX financials along with Agile Therapeutics historical stock prices provide a lot of details about the firm.

Agile Therapeutics Income Statement - Key Financial Ratios